bell
The current prices are delayed by 15 mins, login to check live prices.
Zydus Lifesciences Ltd share price logo

Zydus Lifesciences Ltd

(ZYDUSLIFE)

₹978.50.2%

as on 04:01PM, 13 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals
F&O

Zydus Lifesciences Ltd Analyst Rating

based on 33 analysts

HOLD

46.88%

Buy

31.25%

Hold

21.88%

Sell

Based on 33 analysts offering long term price targets for Zydus Lifesciences Ltd. An average target of ₹1083.36

Source: S&P Global Market Intelligence

Zydus Lifesciences Ltd Share analysis

Zydus Lifesciences Ltd price forecast by 33 analysts

Upside of10.72%

High

₹1380

Target

₹1083.36

Low

₹794

Zydus Lifesciences Ltd target price ₹1083.36, a slight upside of 10.72% compared to current price of ₹978.5. According to 33 analysts rating.

Source: S&P Global Market Intelligence

Zydus Lifesciences Ltd Performance

  • Day's Low

    Day's High

    ₹955.05
    ₹981.45
  • 52 Week's Low

    52 Week's High

    ₹633.3
    ₹1,324.3
1 Month Return+ 2.2 %
3 Month Return-12.31 %
1 Year Return+ 51.99 %
Previous Close₹976.50
Open₹981.00
Volume6.51L
Upper Circuit-
Lower Circuit-
Market Cap₹98,258.75Cr

Zydus Lifesciences Ltd Key Statistics

P/E Ratio22.94
PEG Ratio1.54
Market Cap₹98,258.75 Cr
P/B Ratio6.43
EPS38.31
Dividend Yield0.3
SectorPharmaceuticals
ROE23.45

Zydus Lifesciences Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
HOLD₹98,258.75 Cr54.87%0.64₹3,854 Cr₹19,547 Cr
BUY₹14,194.43 Cr-2.04%0.52₹602 Cr₹2,851 Cr
BUY₹71,168.10 Cr33.12%0.56₹3,168 Cr₹29,001 Cr
BUY₹61,090.14 Cr23.08%0.53NANA
BUY₹39,032.84 Cr7.26%0.56₹589 Cr₹3,453 Cr

About Zydus Lifesciences Ltd

Zydus Lifesciences Ltd is a leading pharmaceutical company headquartered in Ahmedabad, India. Incorporated in 1995, the company operates in a number of lines of business, including active pharmaceutical ingredients, formulations, biotechnology, and nutraceuticals.

The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.

Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.

Share Price: ₹978.50 per share as on 13 Dec, 2024 04:01 PM
Market Capitalisation: ₹98,258.75Cr as of today
Revenue: ₹5,113.60Cr as on September 2024 (Q3 24)
Net Profit: ₹898.10Cr as on September 2024 (Q3 24)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
OrganisationZydus Lifesciences Ltd
HeadquartersAhmedabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Zydus Lifesciences Ltd

  • Zydus Lifesciences Faces GST Demand Amid Strong Financials - 29 Nov, 2024

    Zydus Lifesciences received a Rs 1.61 crore GST demand for FY 2017-18 related to Input Tax Credit. The company plans to appeal, stating no material financial impact. Meanwhile, its Q2 FY25 net profit rose 13.8% to Rs 911.20 crore, with a 20.1% revenue increase. The stock rose 2% to Rs 967.35.
  • Zydus Group's IMKELDI Receives USFDA Approval - 27 Nov, 2024

    Shilpa Medicare, in collaboration with Zydus Group's Oncosol and Shorla Oncology, announced USFDA approval for IMKELDI, the first oral liquid form of imatinib for cancer treatment.
  • Zydus Lifesciences Receives Buy Rating with Target Price - 19 Nov, 2024

    Sharekhan recommends buying Zydus Lifesciences with a target price of Rs. 1,078. Despite a 20% y-o-y revenue increase, there were declines in quarterly performance across segments. PAT rose 15% y-o-y but fell 89% q-o-q.
  • Zydus Lifesciences Faces Legal Setback Over Sigrima - 18 Nov, 2024

    Zydus Lifesciences' legal battle over its breast cancer drug Sigrima continues as the Supreme Court denies interim relief, sending the case back to the Delhi High Court. This decision adds uncertainty to Zydus' revenue potential and may impact investor sentiment.
  • Zydus Lifesciences Target Price Adjusted Amid Challenges - 14 Nov, 2024

    Zydus Lifesciences faces mixed reviews; KR Choksey maintains a BUY rating with a target of Rs 1,201, while Motilal Oswal rates it Neutral at Rs 1,010, citing operational performance and market challenges.
  • Zydus Lifesciences Reports Strong Q2 Performance - 13 Nov, 2024

    Zydus Lifesciences reported a 14% increase in Q2 net profit to ₹911 crore, with revenue rising 20% YoY. Analysts maintain positive ratings, with Jefferies and Prabhudas Lilladher suggesting potential upside. The stock gained 1.43%, boosting market cap by ₹1,363 crore.
  • Zydus Lifesciences Acquires Stake in Mylab - 12 Nov, 2024

    Zydus Lifesciences, through its subsidiary Zydus Animal Health and Investments, will acquire a 6.5% stake in Mylab Discovery Solutions from Rising Sun Holdings.

Insights on Zydus Lifesciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 6.80% to 6.85% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 5.59% to 7.52% in Sep 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 74.98% of holdings in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 136.8% return, outperforming this stock by 26.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 62.8% return, outperforming this stock by 10.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 1.41K Cr → 911.2 Cr (in ₹), with an average decrease of 35.8% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, ZYDUSLIFE stock has moved down by -12.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 6.27K Cr → 5.30K Cr (in ₹), with an average decrease of 15.4% per quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 7.24% to 6.57% in Sep 2024 quarter

Zydus Lifesciences Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹4,258.60Cr (-)₹4,343.70Cr (↑2.00%)₹5,366.40Cr (↑23.54%)₹6,046.50Cr (↑12.67%)₹5,113.60Cr (↓15.43%)
Net Income₹779.80Cr (-)₹733.50Cr (↓5.94%)₹1,229.00Cr (↑67.55%)₹1,463.60Cr (↑19.09%)₹898.10Cr (↓38.64%)
Net Profit Margin18.31% (-)16.89% (↓7.76%)22.90% (↑35.58%)24.21% (↑5.72%)17.56% (↓27.47%)
Value in ₹ crore
Details2021202220232024
Total Assets₹18,593.30Cr (-)₹17,876.60Cr (↓3.85%)₹20,675.60Cr (↑15.66%)₹24,264.70Cr (↑17.36%)
Total Liabilities₹5,848.80Cr (-)₹4,636.10Cr (↓20.73%)₹7,036.20Cr (↑51.77%)₹8,548.20Cr (↑21.49%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹1,180.60Cr (-)₹2,227.20Cr (↑88.65%)₹1,272.20Cr (↓42.88%)₹1,078.20Cr (↓15.25%)₹1,999.10Cr (↑85.41%)

Index Inclusions

Nifty Alpha 50

₹58,688.25

-0.57 (-337.65%)

Nifty 500

₹23,358.95

0.44 (102.55%)

S&P BSE Dividend Stability

₹1,039.17

0.5 (5.22%)

NIFTY 100

₹25,724.60

0.7 (178.2%)

Nifty Healthcare

₹14,351.20

-0.08 (-11.45%)

Nifty Next 50

₹72,965.95

-0.16 (-116.65%)

BSE Healthcare

₹44,049.87

-0.29 (-127%)

S&P BSE 150 MidCap

₹16,427.23

-0.08 (-13.51%)

BSE 200

₹11,441.71

0.59 (66.92%)

Nifty 200

₹14,035.90

0.57 (79.45%)

S&P BSE 250 LargeMidCap

₹10,858.15

0.56 (60.7%)

S&P BSE Momentum

₹2,322.97

0.08 (1.8%)

S&P BSE Largecap

₹9,650.28

0.7 (67.42%)

Nifty LargeMidcap 250

₹16,330.60

0.29 (47.35%)

Nifty100 Eq Weig

₹32,867.45

0.2 (65.95%)

NIFTY PHARMA

₹22,157.35

-0.32 (-71.95%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

S&P BSE 400 MidSmallCap

₹12,533.73

-0.22 (-27.07%)

BSE 500

₹36,746.91

0.46 (167.61%)

Zydus Lifesciences Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
74.98%
0.00
Foreign Institutions
7.52%
34.61
Mutual Funds
6.57%
-9.18
Retail Investors
6.85%
0.71
Others
4.08%
-24.41

Zydus Lifesciences Ltd Key Indicators

Details20202021202220232024
Return On Equity %14.2513.618.4311.3823.45
Details20202021202220232024
Return On Assets %7.0711.4825.19.4815.91
Details20202021202220232024
Book Value Per Share (₹)101.33126.88166.01173.08197.11
Details20202021202220232024
Earning Per Share (₹)11.4820.8744.6519.7438.31

Zydus Lifesciences Ltd Valuation

Zydus Lifesciences Ltd in the last 5 years

  • Overview

  • Trends

Lowest (7.34x)

March 7, 2022

Today (22.94x)

December 13, 2024

Industry (56.50x)

December 13, 2024

Highest (34.62x)

March 26, 2024

LowHigh

Zydus Lifesciences Ltd Earnings and Dividends

  • Zydus Lifesciences Ltd Earnings Results

    Zydus Lifesciences Ltd’s net profit jumped 13.8% since last year same period to ₹911.20Cr in the Q2 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated -35.83% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Zydus Lifesciences Ltd Dividends May,2024

    In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 0.92%.

    Read More about Dividends

Zydus Lifesciences Ltd Technicals Summary

Bearish

Neutral

Bullish

Bearish

Zydus Lifesciences Ltd is currently in a Bearish trading position according to technical analysis indicators.

FAQs on Zydus Lifesciences Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Zydus Lifesciences Ltd shares.

Zydus Lifesciences Ltd (ZYDUSLIFE) share price today is ₹978.5

Zydus Lifesciences Ltd is listed on NSE

Zydus Lifesciences Ltd is listed on BSE

  • Today’s highest price of Zydus Lifesciences Ltd is ₹981.45.
  • Today’s lowest price of Zydus Lifesciences Ltd is ₹955.05.

PE Ratio of Zydus Lifesciences Ltd is 22.94

PE ratio = Zydus Lifesciences Ltd Market price per share / Zydus Lifesciences Ltd Earnings per share

Today’s traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 6.51L.

Today’s market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹98258.75Cr.

Zydus Lifesciences Ltd(ZYDUSLIFEPrice
52 Week High
₹1324.3
52 Week Low
₹633.3

Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹978.5. It is down -26.11% from its 52 Week High price of ₹1324.3

Zydus Lifesciences Ltd(ZYDUSLIFE) share price is ₹978.5. It is up 54.51% from its 52 Week Low price of ₹633.3

Zydus Lifesciences Ltd(ZYDUSLIFEReturns
1 Day Returns
2%
1 Month Returns
2.2%
3 Month Returns
-12.31%
1 Year Returns
51.99%